Ardelyx, Inc.
Description
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
About
CEO
Mr. Michael G. Raab
Employees
267
Instrument type
Common Stock
Sector
Healthcare
Industry
Biotechnology
MIC code
XNMS
Address
400 Fifth Avenue, Waltham, MA 02451, United States
×
![Enlarged Chart]()
Oscillators
Invalid data format
Summary
Invalid data format
Moving Averages
Invalid data format
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Oct 30, 2025 | — | — | — | — |
| Jul 30, 2025 | — | — | — | — |
| Apr 30, 2025 | — | — | — | — |
| Feb 20, 2025 | — | — | — | — |
| Aug 2, 2024 | -0.11 | -0.07 | 0.04 | -36.36% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 2 | — | 4 |
| Average estimate | — | -0.13 | — | -0.12 |
| Low estimate | — | -0.15 | — | -0.47 |
| High estimate | — | -0.10 | — | 0.20 |
| Last year EPS | — | -0.11 | — | -0.19 |
[stock_revenue_estimate]
Growth estimates
Current qtr
99.380%
Next qtr. (Mar 2025)
-13.640%
Current year
37.540%
Next year (Dec 2025)
33.640%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 124.46M | 52.16M | 10.10M | 7.57M | 5.28M |
| Cost of revenue | 17.80M | 4.12M | 1.00M | 145,000 | 600,000 |
| Gross profit | 106.66M | 48.04M | 9.10M | 7.43M | 4.68M |
| Operating expense | |||||
| Research & development | 35.54M | 35.20M | 91.14M | 65.05M | 71.68M |
| Selling general and admin | 134.40M | 76.60M | 72.30M | 33.15M | 24.27M |
| Other operating expenses | — | — | — | — | — |
| Operating income | -63.28M | -63.76M | -154.35M | -90.78M | -91.26M |
| Non operating interest income | |||||
| Income | — | — | — | — | — |
| Expense | 8.87M | 5.07M | 4.50M | 5.10M | 5.73M |
| Other income expense | 6.63M | 1.63M | 687,000 | 1.57M | 2.35M |
| Pretax income | -65.52M | -67.20M | -158.16M | -94.31M | -94.64M |
| Tax provision | 547,000 | 8,000 | 4,000 | 2,000 | 303,000 |
| Net income | -66.07M | -67.21M | -158.17M | -94.31M | -94.94M |
| Basic EPS | -0.30 | -0.42 | -1.52 | -1.05 | -1.47 |
| Diluted EPS | -0.30 | -0.42 | -1.52 | -1.05 | -1.47 |
| Basic average shares | 219.33M | 158.69M | 104.21M | 89.58M | 64.48M |
| Diluted average shares | 219.33M | 158.69M | 104.21M | 89.58M | 64.48M |
| EBITDA | -55.35M | -60.98M | -150.85M | -86.67M | -86.41M |
| Net income from continuing op. | -66.07M | -67.21M | -158.17M | -94.31M | -94.94M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 297.58M | 190.07M | 149.91M | 201.56M | 259.78M |
| Current assets | |||||
| Cash | 2.83M | 11.83M | 1.25M | 781,000 | 3.12M |
| Cash equivalents | 18.64M | 84.31M | 71.18M | 90.25M | 178.01M |
| Cash and cash equivalents | 21.47M | 96.14M | 72.43M | 91.03M | 181.13M |
| Other short term investments | 162.83M | 27.77M | 44.26M | 95.45M | 66.38M |
| Accounts receivable | 22.03M | 7.73M | 502,000 | — | — |
| Other receivables | — | — | — | — | 750,000 |
| Inventory | 12.45M | 3.28M | — | — | — |
| Prepaid assets | 18.93M | 13.57M | 9.41M | 8.20M | 3.80M |
| Restricted cash | — | — | — | — | — |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 8.41M | 5.11M | 7.05M | 8.20M | 3.80M |
| Non current assets | |||||
| Properties | 5.64M | 9.34M | 20.23M | 9.54M | 11.21M |
| Land and improvements | — | — | — | — | — |
| Machinery furniture equipment | 2.43M | 2.09M | 2.03M | 1.13M | 870,000 |
| Construction in progress | — | — | — | — | — |
| Leases | 8.73M | 8.75M | 8.75M | 7.99M | 7.95M |
| Accumulated depreciation | -10.20M | -9.66M | -15.89M | -14.45M | -12.63M |
| Goodwill | — | — | — | — | — |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | — | — | — | — | — |
| Investments and advances | — | — | — | 2.11M | — |
| Other non current assets | 40.64M | 25.95M | 1.15M | 552,000 | 314,000 |
| Total liabilities | 130.76M | 91.74M | 67.30M | 75.45M | 73.13M |
| Current liabilities | |||||
| Accounts payable | 11.14M | 10.86M | 4.28M | 5.63M | 2.19M |
| Accrued expenses | 13.00M | 9.84M | 6.19M | 5.00M | 5.53M |
| Short term debt | 4.44M | 30.61M | 35.76M | 6.28M | 3.79M |
| Deferred revenue | 7.18M | 4.21M | — | 4.18M | 4.54M |
| Tax payable | — | — | — | — | — |
| Pensions | 12.60M | 7.55M | 5.42M | 5.67M | 4.45M |
| Other current liabilities | 2.04M | 2.54M | 1.17M | 1.66M | 1.72M |
| Non current liabilities | |||||
| Long term debt | 51.55M | 5.86M | 9.75M | 47.03M | 50.91M |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | — | — | — | — | — |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | — | — | — | — | — |
| Shareholders equity | |||||
| Common stock | 23,000 | 20,000 | 13,000 | 9,000 | 9,000 |
| Retained earnings | -846.20M | -780.14M | -712.93M | -554.77M | -460.45M |
| Other shareholders equity | 224,000 | -54,000 | -6,000 | -4,000 | 20,000 |
| Total shareholders equity | 166.82M | 98.33M | 82.62M | 126.11M | 186.66M |
| Additional paid in capital | 1.01B | 878.50M | 795.54M | 680.87M | 647.08M |
| Treasury stock | — | — | — | — | — |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||
| Net Income | -66.07M | -67.21M | -158.17M | -94.31M | -94.94M | -91.30M | -64.34M | -112.39M | -29.62M | -3.21M | -6.56M | -9.79M |
| Depreciation | 1.29M | 1.14M | 2.81M | 2.54M | 2.50M | 2.68M | 2.64M | 1.30M | 829,000 | 302,000 | 592,000 | 675,000 |
| Deferred Taxes | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | 13.53M | 10.75M | 12.04M | 10.58M | 9.94M | 9.23M | 9.59M | 5.32M | 2.63M | 1.69M | 352,000 | 473,000 |
| Other Non-Cash Items | 4.91M | 6.10M | 2.69M | 2.56M | 3.30M | 792,000 | 567,000 | 540,000 | 458,000 | 1.59M | 3.51M | 950,000 |
| Accounts Receivable | -14.30M | -7.23M | -502,000 | 750,000 | 4.34M | 10.71M | -10.80M | — | 2.58M | 3.85M | -3.36M | -3.07M |
| Accounts Payable | 279,000 | 6.58M | -1.35M | 3.44M | 39,000 | -2.73M | -1.03M | 2.15M | -371,000 | 831,000 | 1.14M | -105,000 |
| Other Assets & Liabilities | -22.48M | -23.33M | -2.30M | -2.97M | 2.65M | -506,000 | 68,000 | 795,000 | -47.05M | 6.88M | 7.28M | 32.66M |
| Operating Cash Flow | -82.83M | -73.19M | -144.78M | -77.41M | -72.18M | -71.13M | -63.30M | -102.29M | -70.54M | 11.93M | 2.94M | 21.80M |
| Investing Activities | ||||||||||||
| Capital Expenditures | -344,000 | 1.74M | -1.87M | -324,000 | -325,000 | -311,000 | -2.36M | -4.87M | -3.45M | -1.86M | -278,000 | -128,000 |
| Net Intangibles | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Acquisitions | — | — | — | — | — | — | — | — | — | — | — | — |
| Purchase of Investments | -215.23M | -50.33M | -72.74M | -150.85M | -102.67M | -169.03M | -84.01M | -133.81M | — | — | — | — |
| Sale of Investments | 84.32M | 67.00M | 125.55M | 119.73M | 126.37M | 139.45M | 151.66M | 7.60M | — | — | — | — |
| Investing Cash Flow | -131.25M | 18.42M | 50.95M | -31.44M | 23.37M | -29.89M | 65.29M | -131.08M | -3.45M | -1.86M | -278,000 | -128,000 |
| Financing Activities | ||||||||||||
| Long-Term Debt Issuance | 22.39M | 26.97M | — | — | — | 49.29M | — | — | — | — | — | — |
| Long-Term Debt Payments | — | -33.04M | -19.44M | -125,000 | — | — | — | — | — | — | — | — |
| Other Financing Charges | 3.50M | 9.58M | -106,000 | — | — | — | — | — | 30,000 | -2,000 | -2,000 | — |
| Financing Cash Flow | 145.12M | 75.14M | 81.60M | 20.92M | 154.90M | 103.06M | — | 190.57M | 74.35M | 61.24M | -3,000 | -20,000 |
| Other Cash Details | ||||||||||||
| End Cash Position | 21.47M | 96.14M | 72.43M | 91.03M | 181.13M | 78.77M | 75.38M | 74.60M | 107.00M | 107.29M | 34.44M | 32.90M |
| Income Tax Paid | 51,000 | 6,000 | 4,000 | 1,000 | 2,000 | 4,000 | 3,000 | — | 69,000 | — | 160,000 | — |
| Interest Paid | 4.24M | 2.90M | 3.47M | 4.20M | 4.92M | — | — | — | — | — | — | — |
| Free Cash Flow | -90.06M | -70.10M | -154.42M | -81.76M | -76.81M | -70.59M | -67.55M | -97.40M | -75.29M | 11.54M | 1.53M | 21.85M |
Error: Invalid format in Holders JSON file.
Article
Ardelyx to Report Full Year and Fourth Quarter 2024 Financial Results on February 20, 2025
WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, February 20, 2025, at 8:00 a.m.
Jan 30, 2025
Article
Ardelyx (ARDX) Moves 16.0% Higher: Will This Strength Last?
Ardelyx (ARDX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Jan 14, 2025
Article
Ardelyx Provides Update on Increasing Commercial Momentum and 2025 Strategic Priorities
Company achieved significant commercial progress in 2024, finishing with total U.S. net product sales revenue of approximately $319 million (unaudited)
Jan 13, 2025
